News & Updates

Female gout patients at higher risk of SARS-CoV-2 infection, severe sequelae
Female gout patients at higher risk of SARS-CoV-2 infection, severe sequelae
18 Sep 2022

Despite being vaccinated against COVID-19, women with gout have an excess risk of developing SARS-CoV-2 infection as well as severe sequelae from it, according to a study.

Female gout patients at higher risk of SARS-CoV-2 infection, severe sequelae
18 Sep 2022
Smoking during surgical mask use may impair vascular function
Smoking during surgical mask use may impair vascular function
16 Sep 2022
MRNA booster shot durably bolsters defenses against severe COVID-19
MRNA booster shot durably bolsters defenses against severe COVID-19
14 Sep 2022
Nirmatrelvir conferred protection in older adults during the Omicron outbreak
Nirmatrelvir conferred protection in older adults during the Omicron outbreak
13 Sep 2022
3D-printed masks a good alternative to N95 respirators
3D-printed masks a good alternative to N95 respirators
12 Sep 2022
Tuberculosis survivors at risk of stroke
Tuberculosis survivors at risk of stroke
11 Sep 2022

Patients who have been treated for tuberculosis appear to have an elevated risk of ischaemic stroke compared with their counterparts who have never had the infection, according to a study.

Tuberculosis survivors at risk of stroke
11 Sep 2022
CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
09 Sep 2022 bySarah Cheung

First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.

CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
09 Sep 2022